These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26988703)

  • 1. Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
    Chang YH; Li WH; Chang Y; Peng CW; Cheng CH; Chang WP; Chuang CM
    BMC Cancer; 2016 Mar; 16():235. PubMed ID: 26988703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
    Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
    Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study.
    Chao WT; Chien CH; Lai CR; Wu HJ; Chuang CM
    Cancer Control; 2019; 26(1):1073274819863778. PubMed ID: 31343898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.
    Lu CH; Chang YH; Lee WH; Chang Y; Peng CW; Chuang CM;
    Chemotherapy; 2016; 61(5):240-8. PubMed ID: 26930357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
    Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
    Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
    Chang YH; Lu CH; Yen MS; Lee WH; Chang Y; Chang WP; Chuang CM
    Chin J Cancer; 2016 May; 35():45. PubMed ID: 27160669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer.
    Teo MC
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):3-8. PubMed ID: 24247932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
    Jaaback K; Johnson N
    Cochrane Database Syst Rev; 2006 Jan; (1):CD005340. PubMed ID: 16437527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
    Duska LR; Java JJ; Cohn DE; Burger RA
    Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Residual Disease Status after Primary Cytoreductive Surgery in Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Carcinoma and Long-Term Progression-Free Survival].
    Otsuka I; Matsuura T
    Gan To Kagaku Ryoho; 2016 Dec; 43(13):2547-2551. PubMed ID: 28028263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
    Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
    Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
    Gao B; Lindemann K; Anderson L; Fereday S; Hung J; Alsop K; Tothill RW; Gebski V; Kennedy C; Balleine RL; ; Harnett PR; Bowtell DD; DeFazio A
    Gynecol Oncol; 2016 Sep; 142(3):458-64. PubMed ID: 27444035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical activity of melflufen (J1) in ovarian cancer.
    Carlier C; Strese S; Viktorsson K; Velander E; Nygren P; Uustalu M; Juntti T; Lewensohn R; Larsson R; Spira J; De Vlieghere E; Ceelen WP; Gullbo J
    Oncotarget; 2016 Sep; 7(37):59322-59335. PubMed ID: 27528037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.